Eph receptor tyrosine kinases and their ephrin ligands have been implicated in embryonic vascular development and in in vivo models of angiogenesis. Eph proteins may also regulate tumor neovascularization, but this role has not been previously investigated. To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells. By immunohistochemistry, the ephrin-A1 ligand and one of its receptors, EphA2, were detected throughout tumor vasculature. Double-labeling with anti-CD34 antibodies demonstrated that both ephrin-A1 and EphA2 were expressed in xenograft endothelial cells and also tumor cells. Furthermore, EphA2 was tyrosinephosphorylated in the xenograft tumors, indicating that it was activated, presumably by interacting with ephrin-A1. Ephrin-A1 and EphA2 were also detected in both the vasculature and tumor cells of surgically removed human cancers. In an in vitro angiogenesis model, a dominant negative form of EphA2 inhibited capillary tube-like formation by human umbilical vein endothelial cells (HUVECs), demonstrating a requirement for EphA receptor signaling. These data suggest that ephrin-A1 and EphA2 play a role in human cancers, at least in part by in¯uencing tumor neovascularization. Eph proteins may represent promising new targets for antiangiogenic cancer treatments. Oncogene (2000) 19, 6043 ± 6052.
Introduction
Receptor tyrosine kinases play key roles in the formation of the embryonic circulatory system (Folkman and D'Amore, 1996; Gale and Yancopoulos, 1999; Hanahan, 1997; Risau, 1997; Risau and Flamme, 1995) and also control pathological angiogenesis, such as tumor angiogenesis (Folkman, 1995; Hanahan and Folkman, 1996) . The Eph receptor tyrosine kinases, which regulate the spatial organization of cells in the developing nervous system, have been recently shown to also play a role in angiogenesis (Gale and Yancopoulos, 1999; Stein et al., 1998) .
The Eph receptors, with fourteen identi®ed members, comprise the largest family of receptor tyrosine kinases (Eph-Nomenclature-Committee, 1997) . The Eph family is divided into two groups based on sequence homology, EphA and EphB. The ligands for the Eph receptors are the ephrins, which exhibit the distinctive property of being membrane-anchored. Five of the eight ephrins are linked to the plasma membrane through a glycosyl phosphatidylinositol (GPI)-linkage (ephrin-A subclass), while three are transmembrane (ephrin-B subclass). Ephrin-A ligands bind preferentially to EphA receptors and ephrin-B ligands bind preferentially to EphB receptors. Within each (A or B) subclass, receptor-ligand interactions are highly promiscuous and in vivo interactions likely occur where a receptor and ligand of the same subclass are coexpressed.
In an in vivo rat corneal angiogenesis assay, the angiogenic eects of tumor necrosis factor (TNF) a were shown to depend on ephrin-A1 (Pandey et al., 1995) , suggesting that induction of ephrin-A1 mediated the TNFa angiogenic signal. Ephrin-A1 has also been shown to induce the assembly of cultured human umbilical vein endothelial cells (HUVECs) into capillary-like structures in vitro (Daniel et al., 1996) . A role for ephrin-A1 in tumor endothelial cells has been proposed (Bobik et al., 1997) but not demonstrated. Three other Eph receptors (EphB2, EphB3 and EphB4) and their ligands (ephrin-B1 and ephrin-B2) were recently implicated in the formation of the circulatory system of the mouse embryo (Adams et al., 1999; Gerety et al., 1999; Wang et al., 1998) . Mice lacking ephrin-B2, and a proportion of double mutants de®cient in EphB2 and EphB3, exhibit severe defects in the remodeling of the embryonic vascular system. Notably, ephrin-B2 is expressed in arterial endothelial cells and EphB4 exhibits a complementary expression pattern in venous endothelial cells, suggesting that expression of the receptor/ligand pair establishes boundaries between arterial and venous endothelial cells.
Although tumors, particularly in the more malignant stages, are typically disorganized, they support formation of a circulation system suciently functional to allow tumor survival and growth. Indeed, many angiogenic factors are expressed by tumor cells, endothelial cells colonizing tumors, and macrophages in®ltrating the tumor (Bobik et al., 1997) . Several Eph receptors are overexpressed in tumors (Hirai et al., 1987; Kiyokawa et al., 1994; Maru et al., 1988 Maru et al., , 1990 , particularly during the more invasive stages of tumor progression (Andres et al., 1994; Berclaz et al., 1996; Easty et al., 1995; reviewed by Dodelet and Pasquale, 2000) , but in most cases their cellular distribution has not been characterized. In particular, it has been unclear whether Eph receptors and ephrins are expressed in tumor vasculature, which continuously undergoes remodeling. By screening with a panel of antibodies to Eph receptors and ephrins, we detected the ephrin-A1 ligand and one of its receptors, EphA2, in the blood vessels of human tumor xenografts grown in nude mice as well as surgically removed human tumors. We propose, therefore, that EphA2 and ephrin-A1 play a role in tumor neovascularization, a process essential for tumor growth and malignant progression (Hanahan and Folkman, 1996) .
Results

Immunolocalization of ephrin-A1 and EphA2 in the blood vessels of tumor xenografts
Blood vessels were easily identi®ed in the well vascularized marginal areas of tumors derived from MDA-MB-435 breast cancer cells and KS1767 Kaposi's sarcoma cells. In contrast, the central areas of the tumors were necrotic. We focused, therefore, on the marginal areas for immunohistochemical screening to identify Eph receptors and ephrin ligands expressed in tumor vasculature. Among the antibodies tested (Eberhart et al., 2000; Holash and Pasquale, 1995; Soans et al., 1994 Soans et al., , 1996 , antibodies to the ephrin-A1 ligand and the EphA2 receptor most prominently labeled blood vessels and tumor cells of both the MDA-MB-435 and KS1767 tumor xenograft models.
Two dierent anti-ephrin-A1 antibodies were used to stain MDA-MB-435 ( Figure 1A ,B) and KS1767 ( Figure 1H,I ) tumor sections. Similar staining patterns were obtained with the two antibodies, which show that ephrin-A1 is highly expressed in the tumor neovasculature. Ephrin-A1 immunoreactivity was also detected in the MDA-MB-435 and KS1767 tumor cells. To examine the distribution of receptors for ephrin-A1 (Flanagan and Vanderhaeghen, 1998) , we used an ephrin-A1 Fc probe to stain MDA-MB-435 tumor sections ( Figure 1D ). Receptors that bound the ephrin-A1 Fc probe were detected at similar levels in the vasculature as well as the tumor cells. The staining with ephrin-A1 Fc was similar to the staining obtained with two dierent antibodies to the EphA2 receptor ( Figure 1E,F) . In KS1767 tumors, both vasculature and tumor cells also expressed EphA2 at similar levels ( Figure 1J ). The ephrin-A1 and EphA2 immunoreactivities were abolished by preincubating the primary antibody with the corresponding antigen ( Figure  1C ,G), indicating that the staining was speci®c.
To con®rm that ephrin-A1 and EphA2 are indeed expressed in tumor endothelial cells, we used immunouorescence double-labeling to correlate their localization with the localization of vascular markers. MDA-MB-435 tumor sections were stained with anti-CD34 antibodies together with either anti-ephrin-A1 ( Figure  2A ± C) or anti-EphA2 antibodies ( Figure 2D ± F). CD34 is a marker for both mature and immature endothelial cells (Asahara et al., 1997; Baumheter et al., 1993; Gasparini, 1997) . The observed colocalization with CD34 demonstrated that in the tumor xenograft, ephrin-A1 is prominently expressed in endothelial cells lining the blood vessels. Lower levels of ephrin-A1 expression were detected in the tumor cells. EphA2 was also colocalized with CD34, indicating that it is expressed in tumor endothelial cells. However, EphA2 was less prominent in endothelial cells compared to ephrin-A1. Double-labeling experiments with antibodies to CD31 (PECAM-1), another marker of tumor endothelial cells (Fox et al., 1995; Gasparini, 1997) , yielded similar results (not shown).
Detection of ephrin-A1 and EphA2 in tumor xenografts by immunoblotting
We con®rmed ephrin-A1 and EphA2 expression in MDA-MB-435 and KS1767 tumors by immunoprecipitation followed by immunoblotting (Figure 3 ). In addition, by probing EphA2 immunoprecipitates with anti-phosphotyrosine antibodies, we determined that the EphA2 receptor is phosphorylated on tyrosine in these tumors and is, therefore, likely to be activated by a ligand (Kalo and Pasquale, 1999; van der Geer et al., 1994) . This is consistent with a colocalization of EphA2 and ephrin-A1 in both endothelial and tumor cells. Interestingly, the level of EphA2 tyrosine phosphorylation was higher in Kaposi's xenograft tissue, consistent with the higher ephrin-A1 expression in these tumors.
Ephrin-A1 and EphA2 expression in human tumors, hyperplasias, and mastopathia fibrosa
We investigated whether ephrin-A1 and EphA2 are expressed in the vasculature of human tumors, as suggested by the expression of these Eph proteins in the vasculature of human tumor xenografts grown in mice. The expression patterns of ephrin-A1 and EphA2 in human malignant tumors are summarized in Table 1 (top half). In almost all human malignant tumor samples, ephrin-A1 and EphA2 were expressed in blood vessels as well as in tumor cells. There was no correlation between ephrin-A1 and EphA2 staining intensities and the degree of tumor malignancy (Table  1) . Figures 4A ± D show examples of the expression patterns of ephrin-A1 and EphA2 in human breast cancers. In these tumors, both ephrin-A1 and EphA2 were detected in blood vessels and tumor cells.
To determine whether ephrin-A1 and EphA2 are colocalized in the same blood vessels, we compared adjacent tumor sections, in which the same blood vessels could be identi®ed ( Figure 4C,D) . We indeed found that ephrin-A1 and EphA2 are coexpressed in blood vessels, in addition to the breast tumor cells. We also examined the boundaries of malignant tumor tissue with the surrounding stroma in the human tumor samples ( Figure 4E,F) . Blood vessels in the stroma prominently expressed ephrin-A1 and EphA2.
In the limited number of human hyperplasia and mastopathia ®brosa samples that we examined, the expression of ephrin-A1 and EphA2 varied widely (Table 1, bottom half). For example, ephrin-A1 and EphA2 were prominently positive in blood vessels and tumor cells in one breast ®broadenoma ( Figure 5A ,B), whereas they were essentially undetectable in another ( Figure 5C ,D). Similar uneven expression was observed in the two mastopathia specimens examined (Table 1) . It was noted, however, that in the tumor, hyperplasia, and mastopathia specimens, ephrin-A1 expression correlated with EphA2 expression.
Capillary tube-like formation assays
To investigate whether EphA2 signaling may play an essential role in the formation of blood vessels, and whether inhibition of EphA2 signaling may represent a viable antiangiogenic cancer treatment, we have used an in vitro angiogenesis assay with transiently transfected HUVECs (Sarma et al., 1992) . Like tumor endothelial cells, HUVECs endogenously express EphA2 (Pandey et al., 1995) . Ephrin-A1 expression is upregulated when these cells are plated on Matrigel (Sarma et al., 1992) . To inhibit EphA2 signaling, we prepared an EphA2-EGFP chimeric protein containing enhanced green¯uorescence protein (EGFP) in place of the cytoplasmic domain. EphA2-EGFP has an intact ligand binding domain. It will, therefore, compete with endogenous EphA receptors for binding to ephrin-A ligands, but will not activate downstream signaling pathways because it does not have a kinase domain. EphA2-EGFP may further inhibit activation of endogenous EphA receptors through a`dominant negative' eect because cross-phosphorylation and activation will not occur in dimers of endogenous full-length EphA receptors and kinase de®cient EphA2-EGFP. Similar kinase domain-de®cient receptor forms have been used previously to inhibit EphA receptor signaling Xu et al., 1999) . To evaluate the role of EphB receptor signaling, we also prepared an analogous EphB4 EGFP con- Paran sections of 23 human malignant tumors (top half), three hyperplasia (®broadenoma and gynekomastia) and two non-neoplastic pathological specimens (mastopathia ®brosa) (bottom half) were stained with anti-ephrin-A1 and anti-EphA2 antibodies. The relative staining intensities in blood vessles and tumor cells are indicated (strong, ++; positive, +; faint, +/7; negative, 7). Each specimen was assigned an arbitrary number. b Tumor grading and staging were performed according to the TNM classi®cation of malignant tumors (UICC), in which G indicates the malignancy grade, pN indicates the extent and localization of lymph node metastases, and pT indicates tumor size penetration into normal tissue (52).
c These were lobular carcinomas, for which grading is not performed. The lung cancers were an anaplastic adenocarcinoma (#19) and a squamous carcinoma (#20); the gastric cancer was a diuse gastric cancer; and the kidney cancer was a clear cell carconoma Ephrin-A1 and EphA2 in tumor vascularization K Ogawa et al Localization of the EGFP¯uorescent proteins to the plasma membrane aided evaluation of the shape of the transfected cells. Unlike untransfected cells and EGFP-F transfected cells, most cells expressing EphA2-EGFP remained round, demonstrating that EphA receptor signaling is required for the dramatic cell elongation occurring when HUVECs form capillary-like tubes on Matrigel ( Figure 6 ). In comparison, EphB4-EGFP only had a small eect on cell elongation. These results further support a role for EphA2 in tumor angiogenesis and suggest that inhibiting the activity of EphA receptors will decrease tumor neovascularization.
Discussion
Here, in the ®rst study to address the role of Eph receptor tyrosine kinases in tumor angiogenesis, we show that the ephrin-A1 ligand and the EphA2 receptor are expressed in tumor blood vessels and may play a role in tumor neovascularization. Ephrin-A1 is highly expressed in embryonic but not adult vasculature (Flenniken et al., 1996; McBride and Ruiz, 1998; Takahashi and Ikeda, 1995) , suggesting a function in neovascularization but not stabilization of mature vessels. Ephrin-A1 was the ®rst ligand for an Eph receptor, EphA2, to be identi®ed (Bartley et al., 1994) . It was independently cloned from HUVECs as a gene induced by TNFa (Holzman et al., 1990) and was proposed to speci®cally mediate the angiogenic eects of TNFa (Pandey et al., 1995) . Here we report ephrin-A1 expression in endothelial cells of human tumor xenografts grown in nude mice and in human tumors. Upregulation of ephrin-A1 expression in tumor endothelial cells could be caused by TNFa and/or other angiogenic factors produced by the tumor. Soluble cytokines derived from tumor tissue could also promote upregulation of ephrin-A1 expression in malignant tumor cells and the vasculature of surrounding stromal tissue.
The staining that we detected in tumor vasculature using an ephrin-A1 Fc probe presumably corresponds to sites of EphA2 receptor expression (Bartley et al., 1994; Flanagan and Vanderhaeghen, 1998) . Of the EphA receptors examined, including EphA3 and EphA4 (unpublished data), only EphA2 showed widespread expression in tumor vasculature. The staining patterns obtained with ephrin-A1 Fc and with two dierent anti-EphA2 antibodies were similar, suggesting either that EphA2 is the only receptor for ephrin-A1 widely expressed in the tumors or that other ephrin-A1 receptors have expression patterns similar to EphA2. Expression of EphA2 has not been reported in embryonic or adult blood vessels, but EphA2 may participate in tumor neovascularization due to aberrant expression in tumor endothelial cells. EphA2 is, however, expressed in cultured endothelial cells (Daniel et al., 1996; Pandey et al., 1995) , suggesting that it may be present in some normal endothelial cells in vivo.
Ephrin-A1 expression in embryonic vasculature is heterogeneous (Takahashi and Ikeda, 1995) and other Eph proteins mark dierent populations of embryonic endothelial cells (Adams et al., 1999; Wang et al., 1998) . In tumors, however, we have found that ephrin-A1 and EphA2 are widely expressed in all types of blood vessels. We detected ephrin-A1 and EphA2 in the vasculature of most malignant tumors and in some hyperplasia and mastopathia ®brosa specimens, and in the blood vessels of the stroma adjacent to tumor tissue. These observations suggest that upregulation of ephrin-A1 and EphA2 in endothelial cells is an early event required for the vascular remodeling occurring in a tissue where a tumor develops.
Ephrin-A1 and EphA2 were found to be upregulated not only in tumor blood vessels but also in tumor cells. This is in agreement with recent reports showing that ephrin-A1 is upregulated in advanced human melanomas (Easty et al., 1999) and EphA2 is upregulated in human prostate cancers as compared with benign prostate epithelium (Walker-Daniels et al., 1999). Ephrin-A1 and EphA2 expressed in tumor cells may in¯uence the interactions of endothelial cells with the surrounding tumor cells. Consistent with this idea, Eph family members are expressed in tissues surrounding blood vessels at sites of sprouting angiogenesis, such as the somites and neural tube (Adams et al., 1999; Wang et al., 1998) . Thus, Eph-mediated interactions between endothelium and surrounding cells could be critical for vascular sprouting and penetration of vessels into both normal and tumor tissues. Ephrin-A1 and EphA2 were coordinately expressed in the tumor samples that we examined, suggesting that their expression is regulated by the same angiogenic cues or that expression of one protein induces the other. Whereas complementary expression of ephrins and Eph receptors results in spatial segregation of receptor-bearing cells from ligand-bearing cells Xu et al., 1999) , the functional consequences of coexpression of ephrins and Eph receptors are unknown. Because overlapping expression patterns allow for extensive interactions, binding of ephrin-A1 to EphA2 in tumor tissue could lead to activation of signaling pathways downstream of EphA2 and possibly ephrin-A1 (Kalo and Pasquale, 1999; van der Geer et al., 1994; Dodelet and Pasquale, 2000; Davy et al., 1999) . Consistent with this hypothesis, we found that EphA2 is phosphorylated on tyrosine in the tumor xenografts. Although our immunoprecipitation experiments could not distinguish between endothelium-and tumor cell-derived EphA2, it is likely that the EphA2 receptor is substantially phosphorylated on tyrosine in endothelial cells because immunostaining showed that ephrin-A1 is expressed in the xenograft vasculature at similar or higher levels than in the tumor cells.
As in normal tissues, angiogenesis in tumors requires endothelial cell proliferation, migration, elongation, assembly, and association with vascular support cells (Hanahan and Folkman, 1996) . Eph receptor signaling has been proposed to in¯uence the movement of neuronal growth cones and the segregation of subpopulations of cells, including endothelial cells (Adams et al., 1999; Flanagan and Vanderhaeghen, 1998; Wang et al., 1998) . Eph receptor signaling in tumors may promote the migration of endothelial cells and their assembly into capillary structures by regulating cytoskeletal plasticity, matrix attachment, and/or intercellular adhesion (Huynh-Do et al., 1999; Pandey et al., 1995; Stein et al., 1998; Zisch et al., 2000) . Accordingly, in vitro ephrin-A1 acts as a chemoattractant for endothelial cells (Pandey et al., 1995) , consistent with a stimualtory role in vascular remodeling. In addition, as we show here, inhibition of EphA receptor activation prevents the cell shape changes that endothelial cells undergo to form blood vessels. Whether signals downstream of ephrin-A1 (Davy et al., 1999) in endothelial cells may also be required for blood vessel formation is an interesting possibility that remains to be investigated. Interestingly, angiogenesis induced by TNFa requires both ephrin-A1 and avb3 integrin (Brooks et al., 1994; Friedlander et al., 1995; Pandey et al., 1995) , suggesting that Eph proteins and integrins regulate angiogenesis coordinately. Indeed, EphA2 activation was recently shown to negatively modulate the activities of integrins and focal adhesion kinase (Miao et al., 2000) .
Several observations indicate that signaling pathways downstream of soluble angiogenic factors and membrane-bound ephrins are linked. First, abnormalities observed in mice lacking ephrins or Eph receptors, including defects in vascular remodeling and endothelial cell interactions with support cells, are highly reminiscent of those seen in mice lacking angiopoietin 1 or its receptor, Tie2 (Sato et al., 1995; Suri et al., 1996) . Second, the angiopoietin receptor, Tie2, has been shown to phosphorylate the cytoplasmic domain of ephrin-B1 (Adams et al., 1999) . Third, in tumor endothelial cells the signaling pathways activated by The ephrins constitute one of three cytokine systems ± in addition to angiopoietins and VEGFs ± that act via receptor tyrosine kinases expressed in endothelial cells. To understand the biochemical mechanisms that govern vascular endothelial cells, further investigations of how ephrins in¯uence blood vessel formation and how their activities complement those of angiopoietins and VEGFs will be required. Interestingly, experiments in progress in our laboratory (to be published elsewhere) show that xenograft tumors derived from transfected MDA-MB-435 cells secreting a soluble form of the EphA2 receptor ectodomain are substantially smaller than control tumors. In these experiments, the secreted EphA2 ectodomain could inhibit the binding of endogenous EphA2 and ephrin-A1 expressed in both the endothelial and the tumor cells. Anticancer treatments targeting ephrin-A1 and EphA2 may be particularly eective because they could both suppress tumor neovascularization and also directly aect the tumor cells. It will be critical to the development of novel anticancer therapies to distinguish the eects of inhibiting ephrin-A1/EphA2 activity in tumor vasculature versus tumor cells.
Materials and methods
Antibodies
All rabbit polyclonal antibodies used were anity-puri®ed. Anti-ephrin-A1 antibody #1 was prepared using bacterially expressed human ephrin-A1 as the antigen, as previously described (Magal et al., 1996) . Anti-ephrin-A1 antibody #2 was raised to an Fc fusion protein comprising the ectodomain of mouse ephrin-A1. Human and mouse ephrin-A1 are 86% identical at the amino acid level. The anti-ephrin-A1 antibodies were anity-puri®ed on the corresponding ephrin Fc column and cross-absorbed on a human Fc column (Cappel) to eliminate the anti-Fc antibodies. Anti-EphA2 antibody #1 was to a TrpE-human EphA2 carboxy terminus fusion protein (Lindberg and Hunter, 1990) , which is 97% identical to the corresponding mouse amino acid sequence, and anti-EphA2 antibody #2 was to a carboxy-terminal peptide of human EphA2 (amino acids CGLKDQVNTVGIPI, which are identical in mouse EphA2). Peroxidase-conjugated monoclonal PY-20 anti-phosphotyrosine antibody was from Transduction Laboratories. Monoclonal rat anti-mouse CD34 antibody was from PharMingen (La Jolla, CA, USA).
Tumor xenografts
Tumors were grown in female nude mice (Balb/c/nu/nu) by injecting MDA-MB-435 human breast cancer cells (Price et al., 1990) and KS1767 human Kaposi's sarcoma cells (Herndier et al., 1994) into the mammary fat pad at 8 weeks of age as Figure 5 Ephrin-A1 and EphA2 are expressed in the vasculature of some human benign tumors. Immunoperoxidase of (A,B) specimen #26 in Table 1 and (C,D) specimen #27 with anti-ephrin-A1 antibody #2 (A,C) and anti-EphA2 antibody #2 (B,D). Ephrin-A1 and EphA2 immunoreactivities are prominent in blood vessels and tumor cells of one ®broadenoma specimen (#26, A,B) and very faint in both blood vessels and tumor cells of the other (#27, C,D) described (Pasqualini et al., 1997) . Tumors were grown for 4 weeks for immunoblotting and for 8 weeks for immunohistochemistry. Mice were sacri®ced under Avertin anesthesia (Vacutainer, Flanklin Lakes, NJ, USA) before removing the tumors. All animal experimentation protocols were approved by the Burnham Institute's Animal Research Committee. For immunoblotting, tumors were rapidly frozen in liquid nitrogen and stored at 7808C. For immunohistochemistry, tumors were ®xed in 4% paraformaldehyde, 0.1 M phosphate, pH 7.2, for 6 h at 48C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.
Human tumor specimens
Tumor, hyperplasia, and mastopathia specimens were obtained from 18 patients with breast cancer, two with lung cancer, one with diuse gastric cancer, three with colon carcinoma, one with clear cell kidney cancer, two with breast ®broadenoma, one with gynecomastia, and two with mastopathia ®brosa at the time of mastectomy or excision biopsy at AK Hospital (Vienna, Austria) in the period 1995 ± 98. One patient with breast cancer received chemotherapy to reduce tumor mass before the removal operation. The specimens were ®xed with formalin, dehydrated with ethanol series, and embedded in paran.
Immunohistochemistry
Cryostat sections of tumor xenografts (6 mm thick) were incubated in 0.3% hydrogen peroxide for 30 min at room temperature, preincubated in a humid chamber with 2% normal goat serum in PBS (NGS ± PBS) for 60 min at room temperature, followed by incubation with primary antibodies at a concentration of 1.0 mg/ml (anti-ephrin A1 #2, antiEphA2 #2) or 0.2 mg/ml (anti-ephrin A1 #1, anti-EphA2 #1) in NGS ± PBS overnight at 48C. To remove background due to endogenous avidin and/or biotin binding sites, avidin and biotin (Avidin/Biotin Blocking Kit, Vector Laboratories, Inc., Burlingame, CA, USA) were added to the blocking and the primary antibody solutions, respectively. The sections were incubated with biotinylated goat anti-rabbit IgG, followed by an avidin-biotin peroxidase complex, and developed by immersing in DAB substrate kit according to the manufacturer's instructions (Vectastain Elite ABC kit, Vector Laboratories). After washing with distilled water, the sections were dehydrated with a graded ethanol series and xylene, and mounted with Cytoseal (Stephens Scienti®c, Riverdale, NJ, USA). The speci®city of the staining was veri®ed by preincubating the primary antibodies with the corresponding antigen before use. Staining with ephrin-A1 Fc was similarly carried out, using 2 mg/ml ephrin-A1 Fc, or human Fc as a negative control, followed by a biotinylated goat anti-human Fc antibody.
For double immuno¯uorescence, anti-CD34 antibody was used (2 mg/ml) together with anti-ephrin-A1 #2 antibody (2 mg/ml) or anti-EphA2 #1 antibody (0.5 mg/ml). Goat antirat IgG conjugated with a Texas Red derivative (1 : 200; Alexa 594, Molecular Probes, Inc., Eugene, OR, USA) and goat anti-rabbit IgG conjugated with a FITC derivative (1 : 200; Alexa 488) were used as secondary antibodies. The protocol was the same as described above, except for the elimination of hydrogen peroxide and avidin/biotin treatments. The sections were mounted with Perma¯uor (Immunotech, Fullerton, CA, USA). Paran sections of human specimens, 5 mm thick, were deparanized in xylene and rehydrated with a graded ethanol series. After antigen unmasking with microwave treatment in 10 mM citrate buer, pH 6.0 twice for 4 min, sections were processed as described above for tumor xenograft sections. Anti-ephrin-A1 #2 antibody and anti-EphA2 #2 antibody were used, at a concentration of 2 mg/ml. Sections were photographed with a Nikon Inverted E-300 Microscope equipped with a SPOT cooled color digital camera (Diagnostic Instrument, Inc., Sterling Heights, MI, USA).
Immunoprecipitation and immunoblotting
The tumor xenografts were homogenized in modi®ed RIPA buer (50 mM HEPES pH 7.2, 150 mM sodium chloride, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM sodium¯uoride, 10% glycerol, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate) containing protease inhibitors (1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mg/ml pepstatin). Supernatants were collected after high speed centrifugation and protein concentrations were measured using a BioRad protein assay (BioRad Laboratories, Hercules, CA, USA). For immunoprecipitations, 500 mg of tissue extracts were diluted in RIPA buer and precleared with Staph A or protein G-sepharose (Pharmacia Biotech, Uppsala, Sweden). The samples were incubated overnight at 48C with 10 mg anti-ephrin-A1 #2, 10 mg antiEphA2 #2, or 3 ml normal rabbit serum, and then with additional 15 ml of Staph A or protein G-sepharose for 1 h at 48C. After washing, sample buer with b-mercaptoethanol (for EphA2) or without b-mercaptoethanol (for ephrin-A1) was added and immunoprecipitates were boiled for 3 min, separated on 7.5% (for EphA2) or 15% (for ephrin-A1) polyacrylamide gels, and transferred onto PVDF membrane. The PVDF membrane was incubated for 1 h at room temperature in 1.5% BSA and 3% nonfat dry milk in Trisbuered saline (TBS), and then overnight at 48C in 3% BSA and 0.2% nonfat dry milk in TBS containing 1 mg/ml antiephrin-A1 antibody #1, 1 mg/ml anti-EphA2 antibody #2, or 1 : 5000 anti-phosphotyrosine antibody (horseradish peroxidase conjugated PY20, Signal Transduction Laboratories). Milk was not used with the anti-phosphotyrosine antibodies. After incubation with 0.2 mg/ml protein-A peroxidase (Sigma Chemical Co., St. Louis, MO, USA) in TBS containing 3% BSA and 0.2% nonfat dry milk for 1 h, immunoblots were developed using enhanced chemiluminescence reagents (Amersham, Arlington Heights, IL, USA).
Capillary tube-like formation assay
To construct the EphA2-EGFP plasmid, the region of human EphA2 encoding amino acids 1 ± 563 (GenBank accession number M36395) was ampli®ed by PCR with a 4 : 1 mixture of Taq and Vent polymerases using the sense primer GGAATTCGGACCGAGAGCGAGAAGC and the antisense primer CGGGATCCTTCCTCCTGCGGTGGATA. The ampli®ed PCR product was digested with EcoRI and BamHI at sites introduced with the primers (underlined sequences) and ligated into EcoRI and BamHI digested pEGFP-N1 vector (Clontech Laboratories, Inc.). To construct the EphB4 ± EGFP plasmid, the region of human EphB4 encoding amino acids 1 ± 584 (GenBank accession number U07695) was ampli®ed with Taq and Vent polymerases using the sense primer AGTTCGGATCC-TACCCGAGTGAG and the antisense primer CGGGATCCCGATGAGATACTGTCCGTGTTTG. The ampli®ed PCR product was digested with KpnI (at an internal site) and BamHI (at a site introduced in the antisense primer, underlined). A 5' HindIII to KpnI fragment obtained from full-length EphB4 in pcDNA3 (obtained from Dr David Scadden) and the KpnI to BamHI PCR product were ligated together into HindIII and BamHI digested pEGFP-N2 vector (Clontech). The pEGFP-F plasmid was from Clontech. PCR products were sequenced to con®rm the ampli®ed sequences. Several nucleotide dierences with the published sequence were found in the EphA2 PCR product, which were con®rmed to be present in the original cDNA, i.e. nucleotides 394, 396, and 397 are T instead of A, nt 399 is A instead of T, nt 410 is G instead of C, and nt 1100 is C instead of T. Similarly, nt 1474 ± 1476 of EphB4 were TGT instead of GTG. Protein products were veri®ed by transient transfection into 293 human embryonal kidney cells and immunoblotting with anti-EGFP antibodies (Clontech).
HUVECs were obtained from Clonetics (Clonetics Products; BioWhittaker, Inc., Walkersville, MD, USA), and cultured and maintained in Endothelial Cell Growth Medium (EGM) (Clonetics Products; BioWhittaker, Inc., Walkersville, MD, USA) according to the manufacturer's instructions. The cells used for experiments were from passages 3 ± 6. Transfections were performed with Lipofectin (Life Technologies, Inc.) following the manufacturer's protocol. Cells 60 ± 80% con¯uent were transfected with 0.18 mg DNA per cm 2 and incubated for 2 ± 3 h with the transfection mixture. The transfection mixture was then removed and replaced with fresh EGM. Twenty-four hours after transfection, HUVECs were plated on twelve well plates coated with a thin layer of Matrigel (Collaborative Biomedical Products; Becton Dickinson, Bedford, MA, USA) at a density of 5610 5 cells/well in EGM. The coating was done according to the manufacturer's instructions. Twenty-four hours after plating, cells were either ®xed with 2% paraformaldehyde or left un®xed and photographed with a Nikon Inverted E-300 Microscope equipped with a SPOT cooled color digital camera. Round, elongated, and undetermined morphologies were evaluated in uorescence and phase contrast photographs of the same ®eld. About 900 ± 1200 cells were counted in each group, in four sets of experiments. The transfected cells were identi®ed from their EGFP¯uorescence. Frequencies of round, elongated, and undetermined cell morphologies were compared by using unpaired Student's t-tests (StatView, Abacus Concepts, Inc.).
